Document Detail


Enhancement of thrombolysis in vivo without skin and soft tissue damage by transcutaneous ultrasound.
MedLine Citation:
PMID:  9651144     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Previous studies have shown that transcutaneous ultrasound enhances thrombolysis by streptokinase in animals in vivo; however, skin and soft tissue damage induced by ultrasound energy has been a major limitation. The objective of this study was to examine the efficacy of thrombolysis and damage to skin and soft tissues using a newly designed concentrated ultrasound system with a cooling manifold. Using a rabbit model with iliofemoral arterial thrombotic occlusions, 15 pairs of arteries were randomized to receive ultrasound treatment or no ultrasound treatment. Streptokinase (25,000 unit/kg) was given intravenously. Skin temperature was maintained at 25-33 degrees C when ultrasound energy was applied. The serum level of creatine kinase, lactate dehydrogenase, red blood cell counts, and platelet counts were checked at baseline, after thrombus induction, and after ultrasound treatment. Fifteen of fifteen (100%) iliofemoral arteries were angiographically recanalized after ultrasound treatment. In contrast, only 1/15 (6.7%) contralateral arteries were patent after 1 hour. After the subsequent hour with heparin the patency was 14/15 in the ultrasound treated group and 3/15 in the control group. Histologically, the patent arteries had only minimal focal mural thrombus, whereas the angiographically occluded arteries had occlusive thrombi. There was no histologic evidence of ultrasound induced damage to overlying skin, soft tissues, or arteries. In addition, there was no significant rise of creatine kinase, lactate dehydrogenase, or decrease in red blood cell counts and platelet counts induced by ultrasound. In conclusion, transcutaneous concentrated ultrasound which significantly enhances streptokinase induced thrombolysis in vivo can be delivered without concomitant tissue damage. This simple combination therapy has clinical potential for safely treating patients with arterial or venous thromboses.
Authors:
H Luo; Y Birnbaum; M C Fishbein; T M Peterson; T Nagai; T Nishioka; R J Siegel
Related Documents :
11690674 - Patent ductus arteriozus associated with anomalous origin of the right coronary artery:...
21419904 - The collateral network concept: remodeling of the arterial collateral network after exp...
12574984 - Pulmonary artery calcification in recipient twins of twin to twin transfusion syndrome:...
12487184 - Bilateral pleural effusion and pulmonary edema caused by a fistulous aneurysm of the du...
16999704 - Incompetence of the internal jugular venous valve: spectrum of echo-doppler appearances.
18501584 - Multidisciplinary management of placenta percreta complicated by embolic phenomena.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Thrombosis research     Volume:  89     ISSN:  0049-3848     ISO Abbreviation:  Thromb. Res.     Publication Date:  1998 Feb 
Date Detail:
Created Date:  1998-09-15     Completed Date:  1998-09-15     Revised Date:  2008-11-21    
Medline Journal Info:
Nlm Unique ID:  0326377     Medline TA:  Thromb Res     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  171-7     Citation Subset:  IM    
Affiliation:
Division of Cardiology, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Angiography
Animals
Femoral Artery / radiography
Hot Temperature
Rabbits
Skin / blood supply,  pathology*
Soft Tissue Injuries / prevention & control*
Thrombolytic Therapy / methods*
Ultrasonic Therapy / adverse effects*,  methods*

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Prevention of the influence of fibrin and alpha2-macroglobulin in the continuous measurement of the ...
Next Document:  A kinetic analysis of the interaction of human recombinant tissue factor pathway inhibitor with fact...